EP3500299
COMBINATION OF ZANUBRUTINIB WITH AN ANTI-CD20 OR AN ANTI-PD-1 ANTIBODY FOR USE IN TREATING CANCER
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
18.8.2017EP published:
13.12.2023EP application number:
17841107.0
EPO information:
European Patent Register
Max expiry date:
17.8.2037
Title in English:
COMBINATION OF ZANUBRUTINIB WITH AN ANTI-CD20 OR AN ANTI-PD-1 ANTIBODY FOR USE IN TREATING CANCERLanguage of the patent:
English
Timeline
Today
18.8.2017EP application
13.12.2023EP Publication
Owner
Name:
Beigene Switzerland GmbHAddress:
Aeschengraben 27, 4051 Basel, CH
Inventor
Name:
HU, NanAddress:
Beijing 102206, CN
Name:
WANG, LaiAddress:
Beijing 102206, CN
Name:
SONG, JingAddress:
Beijing 102206, CN
Name:
ZHANG, TongAddress:
Beijing 102206, CN
Name:
LI, KangAddress:
Beijing 102206, CN
Name:
LUO, LusongAddress:
Beijing 102206, CN
Name:
WEI, MinAddress:
Beijing 102206, CN
Name:
WANG, ZhiweiAddress:
Beijing 102206, CN
Name:
GUO, YunhangAddress:
Beijing 102206, CN
Priority
Number:
PCT/CN2016/096082Date:
19.8.2016Country:
WO
Classification
Categories:
A61K 39/395, A61K 31/519, A61K 31/4162, A61P 35/00, C07K 16/28